Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday

Oncolytics Biotech (NASDAQ:ONCY) is expected to release its Q4 2025 results before the market opens on Friday, March 6th. Analysts expect Oncolytics Biotech to post earnings of ($0.06) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Oncolytics Biotech Stock Down 3.6%

NASDAQ ONCY opened at $1.07 on Friday. Oncolytics Biotech has a 52 week low of $0.33 and a 52 week high of $1.51. The company has a 50 day moving average price of $0.99 and a 200 day moving average price of $1.08. The firm has a market cap of $113.58 million, a PE ratio of -3.82 and a beta of 0.99.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ONCY. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. HC Wainwright boosted their target price on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Finally, Wall Street Zen cut Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Oncolytics Biotech has an average rating of “Moderate Buy” and an average target price of $6.25.

Insider Transactions at Oncolytics Biotech

In other news, Director Patricia S. Andrews purchased 35,400 shares of the stock in a transaction on Thursday, February 12th. The stock was bought at an average price of $0.86 per share, with a total value of $30,444.00. Following the transaction, the director owned 78,128 shares in the company, valued at $67,190.08. The trade was a 82.85% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew Aromando purchased 29,600 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were purchased at an average price of $0.86 per share, for a total transaction of $25,456.00. Following the purchase, the insider owned 55,100 shares in the company, valued at approximately $47,386. The trade was a 116.08% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 389,232 shares of company stock worth $348,084. Insiders own 0.10% of the company’s stock.

Hedge Funds Weigh In On Oncolytics Biotech

Hedge funds and other institutional investors have recently bought and sold shares of the business. Scientech Research LLC acquired a new stake in shares of Oncolytics Biotech in the third quarter worth $25,000. Blair William & Co. IL acquired a new position in Oncolytics Biotech during the fourth quarter valued at $28,000. Security National Bank of Sioux City Iowa IA purchased a new stake in Oncolytics Biotech in the fourth quarter valued at $29,000. CIBC Private Wealth Group LLC acquired a new stake in Oncolytics Biotech during the 4th quarter worth about $44,000. Finally, Tocqueville Asset Management L.P. acquired a new stake in Oncolytics Biotech during the 4th quarter worth about $63,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.